New combo therapy aims to tame tough lung cancer
Disease control
Not yet recruiting
This study tests how well people with small cell lung cancer tolerate a new drug, alisertib, when added to standard chemotherapy (paclitaxel). About 50 adults who have already tried at least one prior treatment will take alisertib pills twice daily for a week each cycle, plus IV …
Phase: PHASE2 • Sponsor: Puma Biotechnology, Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC